Description: Easywell Biomedicals, Inc. develops, manufactures, and sells active pharmaceutical ingredients and over-the-counter drug products in the United States and Asia. It develops TLX-001, an anti-cough medicine; TLX-005, an anti-urinary incontinence medicine; TLX-006 for treatment of breast cancer in PMS women; TLX-007 and TLX-004, an anti-depressant; TLX-008 for prevention of pneumocystis pneumonia; TLX-012 for treatment of epilepsy; TLX-017 for treatment of chronic angina; and TLX-011 for treatment of inflammatory lesions of rosacea. The company also develops TWB-201 for Parkinson patch; TLX-501, an urinary medicine; and TLX-502, a pneumonia medicine, as well as provides medical devices. It has a collaborative development agreement with Handa Pharmaceuticals and Handa Neuroscience, LLC for the development of TLX-050 for the treatment of neurological disorders. The company was formerly known as Actherm Inc. and changed its name to Easywell Biomedicals, Inc. in July 2015. Easywell Biomedicals, Inc. was incorporated in 1998 and is headquartered in Hsinchu City, Taiwan.
Home Page: www.easywellbio.com
No.10, Yanfa 2nd Road
Hsinchu City,
30076
Taiwan
Phone:
886 3 666 9596
Officers
| Name | Title |
|---|---|
| Mr. James Aiping Lee Ph.D. | Manager & President |
| Dr. Yu-Hsing Tu Ph.D. | Chief Science Officer |
| Dr. She Bin-Ru Ph.D. | Chief Technical Officer of Regenerative Medicine Division |
Exchange: TWO
Country: TW : Taiwan
Currency: New Taiwan Dollar (NT$)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Health Care Equipment & Services |
| GIC Industry: | Health Care Equipment & Supplies |
| GIC Sub-Industry: | Health Care Equipment |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 9.1625 |
| Price-to-Sales TTM: | 18.5079 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |